These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 37479763)
21. Lim SYM; Alshagga MA; Alshawsh MA; Ong CE; Pan Y Drug Metab Pers Ther; 2021 Aug; 37(1):55-67. PubMed ID: 35146975 [TBL] [Abstract][Full Text] [Related]
22. Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer. Hwang M; Medley S; Shakeel F; Vanderwerff B; Zawistowski M; Kidwell KM; Hertz DL Support Care Cancer; 2022 Sep; 30(9):7355-7363. PubMed ID: 35606478 [TBL] [Abstract][Full Text] [Related]
23. Metabolism of (-)-cis- and (-)-trans-rose oxide by cytochrome P450 enzymes in human liver microsomes. Nakahashi H; Yamamura Y; Usami A; Rangsunvigit P; Malakul P; Miyazawa M Biopharm Drug Dispos; 2015 Dec; 36(9):565-74. PubMed ID: 26126958 [TBL] [Abstract][Full Text] [Related]
24. The Efficacy of Cyclophosphamide Combined with Prednisone in Membranous Nephropathy Patients with Different Cytochrome P450 2B6 Gene Polymorphisms and Analysis of Factors Influencing the Efficacy. Zhang M; Lv Y; Liu H Drug Des Devel Ther; 2022; 16():3655-3662. PubMed ID: 36277605 [TBL] [Abstract][Full Text] [Related]
25. Nonresponse to high-dose bupropion for depression in a patient carrying Stäuble CK; Lampert ML; Mikoteit T; Hatzinger M; Hersberger KE; Meyer Zu Schwabedissen HE Pharmacogenomics; 2020 Nov; 21(16):1145-1150. PubMed ID: 33124517 [TBL] [Abstract][Full Text] [Related]
26. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants. Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283 [TBL] [Abstract][Full Text] [Related]
27. The mechanism and risk factors of clopidogrel-induced liver injury. Zhai Y; Wang L; Yang F; Feng G; Feng S; Cui T; An L; He X Drug Chem Toxicol; 2016 Oct; 39(4):367-74. PubMed ID: 26654298 [TBL] [Abstract][Full Text] [Related]
28. Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms. Calinski DM; Zhang H; Ludeman S; Dolan ME; Hollenberg PF Drug Metab Dispos; 2015 Jul; 43(7):1084-90. PubMed ID: 25934575 [TBL] [Abstract][Full Text] [Related]
29. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial. Gallien S; Journot V; Loriot MA; Sauvageon H; Morlat P; Reynes J; Reliquet V; Chêne G; Molina JM; HIV Med; 2017 Sep; 18(8):537-545. PubMed ID: 28145050 [TBL] [Abstract][Full Text] [Related]
30. Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation. Muñiz P; Andrés-Zayas C; Carbonell D; Chicano M; Bailén R; Oarbeascoa G; Suárez-González J; Gómez Centurión I; Dorado N; Gallardo D; Anguita J; Kwon M; Díez-Martín JL; Martínez-Laperche C; Buño I Front Immunol; 2022; 13():1002959. PubMed ID: 36211438 [TBL] [Abstract][Full Text] [Related]
31. Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula. Carano F; Sarno S; De Fanti S; Serventi P; Bini C; Luiselli D; Pelotti S Ann Hum Biol; 2018 Feb; 45(1):66-71. PubMed ID: 28971704 [TBL] [Abstract][Full Text] [Related]
32. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Rae JM; Soukhova NV; Flockhart DA; Desta Z Drug Metab Dispos; 2002 May; 30(5):525-30. PubMed ID: 11950782 [TBL] [Abstract][Full Text] [Related]
33. The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity. Gao LC; Liu FQ; Yang L; Cheng L; Dai HY; Tao R; Cao SP; Wang D; Tang J Eur J Clin Pharmacol; 2016 Oct; 72(10):1205-1213. PubMed ID: 27439448 [TBL] [Abstract][Full Text] [Related]
34. Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo. Raccor BS; Claessens AJ; Dinh JC; Park JR; Hawkins DS; Thomas SS; Makar KW; McCune JS; Totah RA Drug Metab Dispos; 2012 Jan; 40(1):54-63. PubMed ID: 21976622 [TBL] [Abstract][Full Text] [Related]
35. Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles. Chamboko CR; Veldman W; Tata RB; Schoeberl B; Tastan Bishop Ö Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834793 [TBL] [Abstract][Full Text] [Related]
36. Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma. Veal GJ; Cole M; Chinnaswamy G; Sludden J; Jamieson D; Errington J; Malik G; Hill CR; Chamberlain T; Boddy AV Eur J Cancer; 2016 Mar; 55():56-64. PubMed ID: 26773420 [TBL] [Abstract][Full Text] [Related]
37. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Takada K; Arefayene M; Desta Z; Yarboro CH; Boumpas DT; Balow JE; Flockhart DA; Illei GG Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218 [TBL] [Abstract][Full Text] [Related]
38. Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6. Shibata Y; Tamemoto Y; Singh SP; Yoshitomo A; Hozuki S; Sato H; Hisaka A Drug Metab Pharmacokinet; 2021 Aug; 39():100396. PubMed ID: 33992954 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions. Liu S; Wang Z; Chan E; Zhao Y; Kang J; Zhang X; Tian X Chem Biol Interact; 2022 Jan; 352():109775. PubMed ID: 34910929 [TBL] [Abstract][Full Text] [Related]